Skip to main content

Market Overview

AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure

Share:
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management.
  • The study will evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.
  • Endpoints include overall perioperative opioid use, length of post-anesthesia care unit recovery time, outpatient prescription opioid use over the first 24 hours after discharge home, and adverse events.
  • Data will be compared to the historical matched control patients on buprenorphine treated with standard IV opioids in the perioperative setting.
  • Dsuvia, known as Dzuveo in Europe, is indicated for use in adults to manage acute pain severe enough to require an opioid analgesic for which alternative treatments are inadequate.
  • Price Action: ACRX shares are up 0.25% at $1.51 on the last check Thursday.
 

Related Articles (ACRX)

View Comments and Join the Discussion!

Posted-In: Briefs buprenorphineBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com